非肌层浸润性膀胱癌膀胱灌注治疗专家共识

2019-01-30 中国泌尿外科相关专家组(统称) 中华肿瘤杂志.2019.41(1):42-45.

膀胱癌是常见的恶性肿瘤之一,临床上75%的膀胱癌为非肌层浸润性膀胱癌,术后复发率高。膀胱灌注治疗可以降低膀胱癌复发和进展的风险。根据近年国内外循证医学证据和中国学者对膀胱癌诊治研究的不断深入,本共识对当前国内非肌层浸润性膀胱癌的膀胱灌注治疗进行了探讨,包括膀胱灌注的适应证、禁忌证、灌注治疗的形式和常用药物等。

中文标题:

非肌层浸润性膀胱癌膀胱灌注治疗专家共识

发布日期:

2019-01-30

简要介绍:

膀胱癌是常见的恶性肿瘤之一,临床上75%的膀胱癌为非肌层浸润性膀胱癌,术后复发率高。膀胱灌注治疗可以降低膀胱癌复发和进展的风险。根据近年国内外循证医学证据和中国学者对膀胱癌诊治研究的不断深入,本共识对当前国内非肌层浸润性膀胱癌的膀胱灌注治疗进行了探讨,包括膀胱灌注的适应证、禁忌证、灌注治疗的形式和常用药物等。


拓展指南:膀胱癌相关指南:

相关资料下载:
[AttachmentFileName(sort=100, fileName=非肌层浸润性膀胱癌膀胱灌注治疗专家共识)] GetToolGuiderByIdResponse(projectId=1, id=e601e1c001e27284, title=非肌层浸润性膀胱癌膀胱灌注治疗专家共识, enTitle=, guiderFrom=中华肿瘤杂志.2019.41(1):42-45., authorId=null, author=, summary=膀胱癌是常见的恶性肿瘤之一,临床上75%的膀胱癌为非肌层浸润性膀胱癌,术后复发率高。膀胱灌注治疗可以降低膀胱癌复发和进展的风险。根据近年国内外循证医学证据和中国学者对膀胱癌诊治研究的不断深入,本共识对当前国内非肌层浸润性膀胱癌的膀胱灌注治疗进行了探讨,包括膀胱灌注的适应证、禁忌证、灌注治疗的形式和常用药物等。 , cover=, journalId=null, articlesId=null, associationId=943, associationName=中国泌尿外科相关专家组(统称), associationIntro=null, copyright=0, guiderPublishedTime=Wed Jan 30 00:00:00 CST 2019, originalUrl=, linkOutUrl=, content=膀胱癌是常见的恶性肿瘤之一,临床上75%的膀胱癌为非肌层浸润性膀胱癌,术后复发率高。膀胱灌注治疗可以降低膀胱癌复发和进展的风险。根据近年国内外循证医学证据和中国学者对膀胱癌诊治研究的不断深入,本共识对当前国内非肌层浸润性膀胱癌的膀胱灌注治疗进行了探讨,包括膀胱灌注的适应证、禁忌证、灌注治疗的形式和常用药物等。 <div><br> </div> 拓展指南:<strong>与<font color=red>膀胱癌</font>相关指南:</strong><br><ul><li><a href="https://www.medsci.cn/guideline/show_article.do?id=6fc1d1c001e069b2" title="2019 CUA指南:肌层浸润性膀胱癌" target=_blank>2019 CUA指南:肌层浸润性膀胱癌</a></li> <li><a href="https://www.medsci.cn/guideline/show_article.do?id=8daf11c0016899f2" title="中国非肌层浸润性膀胱癌治疗与监测循证临床实践指南(2018简化版)" target=_blank>中国非肌层浸润性膀胱癌治疗与监测循证临床实践指南(2018简化版)</a></li> <li><a href="https://www.medsci.cn/guideline/show_article.do?id=612811c001682383" title="NCCN临床实践指南:膀胱癌(2019.V1)" target=_blank>NCCN临床实践指南:膀胱癌(2019.V1)</a></li> <li><a href="https://www.medsci.cn/guideline/show_article.do?id=1e4f31c001680ea2" title="膀胱癌诊疗规范(2018年版)" target=_blank>膀胱癌诊疗规范(2018年版)</a></li> <li><a href="https://www.medsci.cn/guideline/show_article.do?id=6f1471c00161223c" title="NCCN临床实践指南:膀胱癌(2018.V5)" target=_blank>NCCN临床实践指南:膀胱癌(2018.V5)</a></li> 更多信息请点击:<a href="https://www.medsci.cn/guideline/list.do?q=%E8%86%80%E8%83%B1%E7%99%8C" target=_blank>有关膀胱癌更多指南</a></ul>, tagList=[TagDto(tagId=34797, tagName=非肌层浸润性膀胱癌), TagDto(tagId=89110, tagName=膀胱灌注治疗)], categoryList=[CategoryDto(categoryId=5, categoryName=肿瘤科, tenant=100), CategoryDto(categoryId=26, categoryName=泌尿外科, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=null, articleKeyword=null, articleKeywordNum=null, guiderKeywordId=null, guiderKeyword=null, guiderKeywordNum=null, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=共识, guiderLanguage=1, guiderRegion=3, opened=0, paymentType=null, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=6788, appHits=370, showAppHits=0, pcHits=4301, showPcHits=3345, likes=92, shares=16, comments=4, approvalStatus=1, publishedTime=Sun Apr 21 19:24:51 CST 2019, publishedTimeString=2019-01-30, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=1, createdBy=null, createdName=qiushida2, createdTime=Sun Apr 21 19:24:51 CST 2019, updatedBy=null, updatedName=null, updatedTime=Sat Jan 06 15:35:59 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=100, fileName=非肌层浸润性膀胱癌膀胱灌注治疗专家共识)])
非肌层浸润性膀胱癌膀胱灌注治疗专家共识
下载请点击:
评论区 (2)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=978094, encodeId=759b9e809425, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210630/bd34754d3b0046c2bd64321e47863622/81281d26ab254ed9803ad3323b1a5f2a.jpg, createdBy=0d5f1677558, createdName=毅哥, createdTime=Wed Jun 30 05:35:24 CST 2021, time=2021-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=914195, encodeId=e67991419549, content=好好学习天天向上, beContent=null, objectType=guider, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5d014978118, createdName=Houqiangcn, createdTime=Wed Jan 06 21:55:00 CST 2021, time=2021-01-06, status=1, ipAttribution=)]
    2021-06-30 毅哥

    学习

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=978094, encodeId=759b9e809425, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210630/bd34754d3b0046c2bd64321e47863622/81281d26ab254ed9803ad3323b1a5f2a.jpg, createdBy=0d5f1677558, createdName=毅哥, createdTime=Wed Jun 30 05:35:24 CST 2021, time=2021-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=914195, encodeId=e67991419549, content=好好学习天天向上, beContent=null, objectType=guider, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5d014978118, createdName=Houqiangcn, createdTime=Wed Jan 06 21:55:00 CST 2021, time=2021-01-06, status=1, ipAttribution=)]
    2021-01-06 Houqiangcn

    好好学习天天向上

    0